Ocular Therapeutix, Inc. (OCUL)

US — Healthcare Sector
Peers: CTMX  ASMB  SPRO  ACHL  TERN  AMLX  ABOS  INZY  XFOR  MREO  PDSB  HOOK  DAWN 

Automate Your Wheel Strategy on OCUL

With Tiblio's Option Bot, you can configure your own wheel strategy including OCUL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol OCUL
  • Rev/Share 0.3517
  • Book/Share 1.5699
  • PB 5.3317
  • Debt/Equity 0.2866
  • CurrentRatio 10.2224
  • ROIC -0.5513

 

  • MktCap 1333341000.0
  • FreeCF/Share -0.8762
  • PFCF -8.9831
  • PE -7.3574
  • Debt/Assets 0.1878
  • DivYield 0
  • ROE -0.588

 

  • Rating C-
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 2
  • D/E Score 2

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation OCUL William Blair -- Outperform -- -- April 8, 2025
Initiation OCUL RBC Capital Mkts -- Outperform -- $17 March 18, 2025
Initiation OCUL Needham -- Buy -- $15 March 11, 2025
Initiation OCUL Scotiabank -- Sector Outperform -- -- Oct. 16, 2024

News

Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue Estimates
OCUL
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Negative

Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.24 per share a year ago.

Read More
image for news Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue Estimates
Ocular Therapeutix: Axpaxli's Dual Trial Strategy And Blockbuster Potential
OCUL
Published: March 06, 2025 by: Seeking Alpha
Sentiment: Positive

Ocular Therapeutix focuses on Axpaxli, a long-acting wet AMD therapy administered every 6-12 months. Dextenza currently drives revenues, but Axpaxli is expected to unlock long-term growth. Ocular has two important Phase 3 trials (SOL-1 and SOL-R), which are key catalysts this year, with data expected by early 2026.

Read More
image for news Ocular Therapeutix: Axpaxli's Dual Trial Strategy And Blockbuster Potential
Ocular Therapeutix (OCUL) Reports Q4 Loss, Tops Revenue Estimates
OCUL
Published: March 03, 2025 by: Zacks Investment Research
Sentiment: Negative

Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.28 per share a year ago.

Read More
image for news Ocular Therapeutix (OCUL) Reports Q4 Loss, Tops Revenue Estimates
Ocular Therapeutix™ to Report Fourth Quarter and Full Year 2024 Results on March 3, 2025
OCUL
Published: February 24, 2025 by: GlobeNewsWire
Sentiment: Neutral

BEDFORD, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced that it plans to host a conference call and webcast on Monday, March 3, 2025, at 8:00 AM ET to discuss recent business progress and financial results for the fourth quarter and full year ended December 31, 2024.

Read More
image for news Ocular Therapeutix™ to Report Fourth Quarter and Full Year 2024 Results on March 3, 2025

About Ocular Therapeutix, Inc. (OCUL)

  • IPO Date 2014-07-25
  • Website https://www.ocutx.com
  • Industry Biotechnology
  • CEO Dr. Pravin U. Dugel M.D.
  • Employees 274

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.